JAYTHARI
Clinical safety rating
cautionComprehensive clinical and safety monograph for JAYTHARI (JAYTHARI).
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It improves glycemic control by enhancing insulin secretion, suppressing glucagon release, and slowing gastric emptying, leading to reduced appetite and caloric intake.
| Metabolism | Metabolized by proteolytic degradation via aminopeptidase and endopeptidase enzymes; not significantly metabolized by CYP450 enzymes. |
| Excretion | Primarily hepatic metabolism; <1% excreted unchanged in urine. Biliary/fecal elimination accounts for ~90% of metabolites. |
| Half-life | Terminal half-life is approximately 25-30 hours in adults, allowing once-daily dosing. Steady-state achieved in 5-7 days. |
| Protein binding | >99% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd ~ 0.7 L/kg, indicating distribution into total body water and some tissue binding. |
| Bioavailability | Oral: ~60% (range 50-70%) due to first-pass metabolism; subcutaneous: ~80%; intravenous: 100%. |
| Onset of Action | Oral: 2-3 hours; Intravenous: within 30 minutes; Subcutaneous: 1-2 hours. |
| Duration of Action | Approximately 24 hours after oral dosing, supporting once-daily regimen. Clinical effect persists for the dosing interval with consistent trough levels. |
| Molecular Weight | 312.37 |
Zavegepant 10 mg intranasal once daily as needed for acute migraine.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for mild or moderate renal impairment. Avoid use in severe renal impairment (eGFR <15 mL/min/1.73 m2) or end-stage renal disease. |
| Liver impairment | No dose adjustment required for mild (Child-Pugh A) or moderate (Child-Pugh B) hepatic impairment. Not recommended in severe (Child-Pugh C) hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment required; consider age-related renal decline and monitor for adverse effects. |
| 1st trimester | Contraindicated due to risk of fetal harm, including congenital malformations. |
| 2nd trimester | Contraindicated due to risk of fetal harm. |
| 3rd trimester | Contraindicated due to risk of fetal hemorrhage or premature closure of ductus arteriosus. |
Clinical note
Comprehensive clinical and safety monograph for JAYTHARI (JAYTHARI).
| Placental transfer | Crosses placenta; demonstrated in animal studies and human placental perfusion models. |
| Breastfeeding | Excreted in breast milk; limited data. Use with caution and monitor infant for adverse effects. |
| Lactation Rating | L3 - Moderately Safe |
| Teratogenic Risk | First trimester: Based on animal studies and limited human data, JAYTHARI is associated with increased risk of major congenital malformations, particularly neural tube defects and cardiovascular anomalies. Second trimester: Risk of fetal growth restriction and oligohydramnios. Third trimester: Risk of premature closure of the ductus arteriosus and persistent pulmonary hypertension in the neonate. |
| Fetal Monitoring | Maternal: Monitor blood pressure, renal function (serum creatinine, BUN, urinalysis), and liver function tests (AST, ALT) at baseline and monthly. Fetal: Serial ultrasound assessments every 4 weeks for fetal growth, amniotic fluid volume, and anatomy. Consider fetal echocardiography if exposed in first trimester. |
| Fertility Effects | Animal studies have shown reversible impairment of spermatogenesis and altered estrous cycles in females. Human data are limited; however, JAYTHARI may reduce fertility in both males and females. Effects on ovarian reserve or sperm parameters are not well characterized. |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
Hypersensitivity to drug or any componentActive peptic ulcer diseaseHistory of bronchial asthmaSevere renal impairment (eGFR <30 mL/min)Third trimester pregnancy
| Precautions | Risk of thyroid C-cell tumors: Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2), Acute pancreatitis: Discontinue if suspected; monitor for signs, Hypoglycemia: Increased risk with concomitant insulin or insulin secretagogues, Diabetic retinopathy complications: Not studied in patients with nonproliferative retinopathy; monitor, Acute kidney injury: May cause GI adverse reactions leading to volume depletion; caution in renal impairment, Severe gastrointestinal disease: Use not recommended in patients with severe gastroparesis, Hypersensitivity reactions: Discontinue if anaphylaxis or angioedema occurs |
| Food/Dietary | Avoid grapefruit and grapefruit juice as they increase drug levels and toxicity risk. Take with food to reduce gastrointestinal irritation. Avoid alcohol due to hepatotoxicity risk. |
| Clinical Pearls | Monitor liver function tests (LFTs) monthly for first 6 months, then every 3 months thereafter. Discontinue if transaminases exceed 3x ULN with bilirubin >2x ULN. Avoid in severe hepatic impairment. Contraindicated in pregnancy (X category). |
| Patient Advice | Take exactly as prescribed, preferably with food to reduce GI upset. · Do not crush or chew tablets; swallow whole. · Avoid alcohol completely during treatment. · Use two reliable forms of contraception during therapy and for 2 months after last dose. · Report any signs of liver injury: jaundice, dark urine, abdominal pain, nausea/vomiting. · Do not take with grapefruit or grapefruit juice. · Stay hydrated and avoid dehydration. · Do not stop abruptly without consulting your doctor. |
Loading safety data…